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Abstract Recent studies in molecular and cellular biology
have shown that tumor growth and metastasis are not
determined by cancer cells alone but also by a variety of
stromal cells. The stroma constitutes a large part of most
solid tumors, and cancer-stromal cell interaction contributes
functionally to tumor growth and metastasis. Angiogenesis
is the result of an imbalance between positive and negative
angiogenic factors released by tumor and host cells into the
microenvironment of the neoplastic tissue. In gastric cancer,
tumor cells and stromal cells produce various angiogenic
factors, including vascular endothelial growth factor,
interleukin-8, and platelet-derived endothelial cell growth
factor. The microenvironment in the gastric mucosa may
also influence the angiogenic phenotype of gastric cancer.
Helicobacter pylori infection increases expression of several
angiogenic factors by tumor cells. Activated fibroblasts and
macrophages in tumor stroma also play an important role in
angiogenesis and tumor progression. We review the current
understanding of cancer-stromal cell interaction as it pertains
to tumor angiogenesis in gastric cancer.
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Abbreviations
CAF Carcinoma-associated fibroblast
TAM Tumor-associated fibroblast
MSC Mesenchymal stem cell
VEGF Vascular endothelial growth factor
IL Interleukin
FGF Fibroblast growth factor
PD-ECGF Platelet-derived endothelial cell growth factor
MVD Microvessel density
H. pylori Helicobacter pylori
COX Cyclooxygenase
CagA Cytotoxin-associated gene A
NF-kB Nuclear factor-kB
MMP Matrix metalloproteinase
MCP Monocyte chemoattractant protein
TGF Transforming growth factor
FAP Fibroblast activation protein
EMT Epithelial-to-mesenchymal transition
Introduction
Cancer tissue consists of both tumor cells and stromal cells,
all of which are surrounded by extracellular matrix. Tumor
growth is determined not only by tumor cells themselves
but also by stromal cells. Recent studies have shown that
interactions between tumor and stromal cells create a
unique microenvironment that is essential for tumor growth
and metastasis [1, 2]. Tumor stroma contains several types
of cells including activated fibroblasts (myofibroblasts),
endothelial cells, and inflammatory cells including macro-
phages (Fig. 1). It has become clear that activated
fibroblasts in cancer stroma are prominent modifiers of
tumor progression. As such, they are called carcinoma-
associated fibroblasts (CAFs) [3]. Angiogenesis, which is
necessary for tumor progression, is also influenced by the
organ microenvironment. Stromal reaction (desmoplasia) is
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neoplasms [4]. The generation of tumor stroma is triggered
by tumor cells and induces the ingrowth of new blood
vessels and mesenchymal cells from the adjacent normal
tissue [5]. However, recent studies revealed that bone
marrow-derived stem cells are integrated into tumor stroma
and differentiate into myofibroblasts and vascular endothe-
lial cells [6, 7].
Gastric cancer is one of the most frequent malignancies
in the world [8]. Previous studies have indicated that a large
number of genetic and epigenetic alterations in oncogenes
and tumor suppressor genes as well as genetic instability
determine the multi-step process of gastric carcinogenesis
[8, 9]. In addition, the molecular events that characterize
gastric cancer differ, depending on the histologic type,
whether intestinal (well-differentiated) or diffuse (poorly
differentiated) gastric cancer [9]. Gastric cancer cells express
a wide array of growth factors, angiogenic factors, and
cytokines that act via autocrine, paracrine, and juxtacrine
mechanisms in the tumor microenvironment [8]. Herein, we
discuss the importance of the organ-specific microenviron-
ment and cancer-stromal cell interaction in the growth and
angiogenesis of human gastric cancer.
Angiogenic Factors in Human Gastric Cancer
Weidner et al. [10] first reported a direct correlation
between the incidence of metastasis and the number and
density of blood vessels in invasive breast cancers. Similar
studies have confirmed this correlation in gastrointestinal
cancers [11–14]. Induction of angiogenesis is mediated by
various molecules released by both tumor and host cells
[15, 16]. Several growth factors that regulate angiogenesis
have been identified. Gastric cancer cells produce various
angiogenic factors, including vascular endothelial growth
factor (VEGF) [13], interleukin (IL)-8 [17], fibroblast
growth factor (FGF)-2 [18], and platelet-derived endothelial
cell growth factor (PD-ECGF) [19].
Among the various angiogenic factors, VEGF (now
termed VEGF-A) is considered one of the strongest
promoters of angiogenesis in gastrointestinal tumors [20].
VEGF-A is released by cancer cells, but fibroblasts and
inflammatory cells in tumor stroma are also sources of host-
derived VEGF-A [21]. VEGF-A, also known as vascular
permeability factor, is a secreted protein that plays a pivotal
role in hyperpermeability of the vessels in addition to
angiogenesis [22]. Several studies have shown a correlation
between VEGF-A expression and microvessel density
(MVD) in human gastric cancer [13]. The prognosis of
patients with VEGF-A-positive tumors is poorer than that
of patients with VEGF-A-negative tumors [12, 14].
For gastric cancer, prognosis is dependent on both the
histologic type and the disease stage [23]. The intestinal-
type gastric cancer tends to metastasize to the liver by
hematogenous dissemination. In contrast, the diffuse-type
gastric cancer is more invasive; peritoneal dissemination is
predominant. We have found that the angiogenic phenotype
differs between intestinal-type and diffuse-type gastric
cancers [13]. Intestinal-type gastric cancer is more depen-
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type but not diffuse-type tumors express high levels of
VEGF-A, levels of that correlate significantly with vessel
counts [13]. In contrast, FGF2 expression is higher in
diffuse-type tumors, especially scirrhous-type cancer [18].
These findings suggest that VEGF-A promotes angiogen-
esis and progression of human gastric cancers, especially
those of the intestinal type.
IL-8 is a multi-functional cytokine that can stimulate
division of endothelial cells. IL-8 can induce migration of
some tumor cells [24] and has been implicated in the
induction of angiogenesis in such diverse diseases as
psoriasis and rheumatoid arthritis and in some malignant
diseases. IL-8 is a known angiogenic factor for human lung
cancer [25, 26] and is also produced by melanomas [27]
and bladder [28] and prostate [29] cancers. In human
gastric cancer, most tumor tissues express IL-8 at levels
higher than those in the corresponding normal mucosa [17].
The level of IL-8 mRNA in neoplasms correlates strongly
with vascularization, suggesting that IL-8 in tumor tissue
regulates neovascularization [17]. Furthermore, gastric
cancer cells transfected with the IL-8 gene were shown to
produce rapidly growing, highly vascular neoplasms at the
orthotopic site (gastric wall) in nude mice [30].
PD-ECGF, an endothelial cell mitogen initially purified
to homogeneity from human platelets, has chemotactic
activity for endothelial cells in vitro and is angiogenic in
vivo [31] .P D - E C G Fw a ss h o w nt ob ei d e n t i c a lt o
thymidine phosphorylase, an enzyme involved in pyrimi-
dine nucleoside metabolism [32]. PD-ECGF expression is
elevated in several types of solid tumor including colon
cancer [33–35]. PD-ECGF is expressed at high levels in
vascular tumors that express low levels of VEGF-A [35]. In
these colon cancers, the major source of PD-ECGF is the
infiltrating macrophages. A positive association between PD-
ECGF expression and MVD has also been reported for
human gastric cancer [19, 36]. In human gastric cancer, PD-
ECGF is expressed more frequently in infiltrating cells than
in tumor epithelium [19]. There is an association between
PD-ECGF expression by infiltrating cells, VEGF-A expres-
sion by tumor epithelium, and vessel counts in intestinal-type
gastric cancer but not in diffuse-type gastric cancer [19].
Lymphangiogenic Factors in Human Gastric Cancer
VEGF-C and VEGF-D are ligands for VEGF receptor
(VEGFR)-3 and VEGFR-2. VEGFR-3 is a tyrosine kinase
receptor that is expressed predominantly in the endothelium
of lymphatic vessels [37]. Alitalo et al. [38] described
VEGF-C as a lymphangiogenic factor that can selectively
induce hyperplasia of the lymphatic vasculature. Other
growth factors are reported to be lymphangiogenic, such as
FGF-2 [39], platelet-derived growth factor (PDGF)-BB
[40], and angiopoietin-2 [41]. VEGF-C/VEGFR-3 signaling
is a key primary proliferation pathway for lymphatic
vessels, whereas angiopoietin-2 is important in later
remodeling stages [41]. Although the importance of FGF-
2, PDGF-BB, and angiopoietin-2 for lymphatic metastasis
of gastric cancer is unknown, a significant correlation
between lymph node metastasis and VEGF-C expression
has been reported in human gastric cancer [42, 43]. VEGF-
C immunoreactivity was associated with lymphatic inva-
sion, lymph node metastasis, and increased MVD, however,
there was no association between VEGF-D immunoreac-
tivity and clinicopathologic features in submucosally
invasive gastric cancer [44]. These results suggest that
VEGF-C is a dominant regulator of lymphangiogenesis in
early-stage human gastric cancer.
Helicobacter pylori (H. pylori) Stimulates Angiogenesis
in Gastric Cancer
The most significant advance in understanding the patho-
genesis of gastric cancer is recognition of the role of H.
pylori in gastric carcinogenesis. H. pylori infection is
thought to contribute significantly to the pathogenesis of
atrophic gastritis and intestinal metaplasia. Epidemiologic
studies have indicated that infection with H. pylori is a risk
factor for gastric cancer, and the WHO/IARC classified this
bacterium as a definite biologic carcinogen in 1994 [45]. In
addition, H. pylori inoculation into the stomach of
Mongolian gerbils was shown to be associated with the
occurrence of chronic gastritis, intestinal metaplasia, and
adenocarcinoma [46, 47]. There are several virulence-
associated H. pylori genes, including cagA, vacA, iceA,
and babA [8]. The cagA-positive strains are associated with
a higher grade of gastritis and higher risk of gastric cancer
than are the cagA-negative strains [48]. The cagA gene is
located within the cag pathogenicity island (PAI). The
cagPAI encodes components of a type IV secretion system,
by which the cagA gene product, CagA, is delivered into
gastric epithelial cells. CagA binds Srk homology 2 (SH2)
domain-containing tyrosine phosphatase SHP-2 and acti-
vates its phosphatase activity. A recent study showed that
H. pylori penetrates normal, metaplastic, and neoplastic
epithelium to cause a strong immune-inflammatory re-
sponse and promote gastric carcinogenesis [49].
In addition to its deregulation of SHP-2 by CagA, H.
pylori is a potent activator of nuclear factor-kB (NF-kB) in
gastric epithelial cells. Activation of NF-kB by H. pylori
infection induces a variety of cytokines, angiogenic factors,
MMPs, and adhesion molecules [50, 51]. We reported
previously that H. pylori-infected gastric cancer patients
have greater tumor vascularity than that of gastric cancer
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pylori infection influences angiogenesis in gastric cancer.
Some studies suggested that the cagA-positive strain of H.
pylori plays an important role in tissue remodeling, angio-
genesis, cancer invasion and metastasis [53–55]. Crabtree et
al. [53] reported that H. pylori infection induces IL-
8 production by gastric epithelium. We found that coculture
of gastric cancer cells with H. pylori induces expression of
mRNAs encoding IL-8, VEGF-A, angiogenin, urokinase-
type plasminogen activator, and MMP-9 by gastric cancer
cells [54]. Wu et al. [55] also reported that H. pylori
influences expression of VEGF-A and MMP-9 and promotes
gastric cell invasion via COX-2- and NF-kB-mediated
pathways. Cox-2 inhibition decreases expression of angio-
genic factors and MMP activity [56].
Role of Tumor-Associated Macrophages (TAMs)
in Angiogenesis
Macrophages belonging to the mononuclear phagocyte
system exhibit functions in endocytosis and cytotoxicity
and secrete more than 100 biologically relevant substances
[57]. Macrophages recruited to tumor stroma are called
TAMs. The role of TAMs in tumor progression is
complicated and wide ranging. Although activated macro-
phages may have anti-tumor activity, tumor cells have been
reported to escape the anti-tumor activity of TAMs [58].
Indeed, removal of macrophages by genetic mutation
reduced tumor progression and metastasis [59]. TAMs are
recruited from circulating monocytes into tissues in
response to chemoattractants, and they interact with tumor
cells to make cancer stroma. One important characteristic of
macrophages is the potential for angiogenic activity.
Activated macrophages produce various factors that induce
angiogenesis in wound repair [60], in chronic inflammatory
diseases such as rheumatoid arthritis [61] and psoriasis
[62], and in atherosclerotic plaques [63]. We previously
reported that macrophage infiltration into tumor tissue
correlates significantly with tumor vascularity in human
esophageal and gastric cancers [64, 65]. Ishigami et al. [66]
also found a direct association between the degree of TAM
infiltration and depth of tumor invasion, nodal status, and
clinical stage in gastric cancer. Macrophage recruitment is
mediated by a variety of chemoattractants, including
monocyte chemoattractant protein-1 (MCP-1/CCL2), mac-
rophage inflammatory protein 1α (MIP-1α/CCL3), regu-
lated upon activation, normal T cell expressed and secreted
(RANTES/CCL5). Of these CC chemokines, MCP-1 is one
of the most potent [67]. We found that MCP-1 produced by
tumor cells is associated significantly with macrophage
infiltration and malignant behavior, such as angiogenesis,
tumor invasion, and lymphatic infiltration [64, 65]. Trans-
fection of the MCP-1 gene into gastric cancer cells causes
strong infiltration of macrophages into tumors and enhanced
tumorigenicity and metastatic potential in a mouse orthotopic
implantation model [68]. Because activated macrophages
produce VEGF-A, IL-8, FGF2, and PD-ECGF, MCP-1
expressed by gastric cancer cells plays a role in angiogenesis
via recruitment and activation of macrophages.
Cyclooxiganase 2 (COX-2) expressed by cancer and
stromal cells has been shown to contribute to tumor
angiogenesis [69]. The expression levels of COX-2, in
both tumor and stromal cells, correlated well with VEGF
levels and MVD in gastric cancer tissue [70]. The CD40
ligand (CD40L)/CD40 interaction has been shown to
induce COX-2 expression in macrophages, fibroblasts,
and endothelial cells [71, 72]. Furthermore, MCP-1 and
CD40L were shown to have a synergistic effect on COX-2
expression and subsequent VEGF production by macro-
phages in gastric cancer [72].
CAFs Promotes Tumor Growth via Angiogenesis
It has been reported that normal fibroblasts inhibit
progression of cancer. Overexpression of transforming
growth factor (TGF)-β and hepatocyte growth factor in
fibroblasts resulted in tumorigenic outgrowth of breast
epithelium, which was inhibited by normal fibroblasts [73].
The inhibition of TGF-β signaling in fibroblasts resulted in
prostate intraepithelial neoplasia, indicating that normal
fibroblasts suppress carcinogenesis [74]. However, numer-
ous studies provided evidence that CAFs indeed promote
the growth of tumors [75, 76]. CAFs show gene expression
profiles that are distinct from those of normal fibroblasts
[77], and they acquire a modified phenotype, similar to
fibroblasts associated with wound healing. Although the
mechanisms that regulate activation of fibroblasts and their
accumulation in tumors are not fully understood, PDGF,
TGF-β, and FGF2 are known to be partly involved in this
process [75, 76, 78]. Many human tumors secrete PDGF
ligands and PDGF receptors are expressed by various
stromal cell populations such as CAFs and pericytes [78–
80]. Inhibition of paracrine PDGF signaling reduces
stromal reaction and disrupt pericyte support, resulted in
destabilizing tumor vasculature and inhibiting angiogenesis
[81–83]. In mouse model of cervical cancer, inhibition of
stromal PDGFR by imatinib suppressed the expression of
FGF-2 (a proangiogenic factor) and FGF-7 (a growth factor
for epithelial cell) by CAFs [82]. Recently, we found that
PDGF receptor is highly expressed by CAFs, pericytes, and
lymphatic endothelial cells in human gastric cancer and
targeting PDGF receptor by imatinib inhibited tumor
growth and metastasis in the orthotopic gastric cancer
model (Sumida et al., unpublished data). Fibroblast activa-
112 Y. Kitadaition protein (FAP) is expressed by activated fibroblasts
during wound healing and within tumor stroma. An
antibody to human FAP, sibrotuzumab, is now under
clinical study in patients with colorectal cancer and non-
small cell lung cancer [84]. CAFs might serve as novel
therapeutic targets in cancer.
Bone Marrow-derived Mesenchymal Stem Cells (MSCs)
as a Source of CAFs
Although CAFs have been implicated in important aspects
of solid tumor biology including tumor growth, angiogen-
esis, and metastasis, sources of CAFs have not been well
defined [85]. There are some candidates for the origins of
CAFs, such as fibroblasts residing in local tissues [76],
periadventitial cells including pericytes and vascular
smooth muscle cells [86], endothelial cells [87], or bone
marrow-derived cells including various stem cells [6].
Worthley et al. [88] recently reported that bone marrow-
derived cells can differentiate CAFs in human gastric
cancer that developed in female recipients of male
allogeneic stem cell transplantation. Major types of stem
cells in the bone marrow are hematopoietic stem cells and
MSCs. MSCs can be defined according to their ability to
self-renew and differentiate into tissues of mesodermal
origin, including bone, cartilage, and adipose and connec-
tive tissues [89]. MSCs were reported to migrate to sites of
tissue injury, sites of inflammation, as well as to stroma in
solid tumor, where they interact with tumor cells [90].
Several studies have implicated molecules such as CXCL12
(SDF-1)/CXCR4, CCL2 (MCP-1)/CCR2, and PDGF in the
tumor-homing ability of MSCs [91–93]. In an in vitro
experiment, MSCs exposed to tumor-conditioned medium
over a prolonged period of time assumed a CAF-like
myofibroblastic phenotype, which promotes tumor cell
growth both in vitro and in vivo [94]. Banerjee et al.
constructed an in vitro model for the tumor-stroma
interaction by culturing MSCs exposed to tumor-
conditioned medium (representing CAFs), tumor cells,
and differentiated HL60/U937 cells as surrogates for
TAM, and found that the presence of CAFs and TAMs
promotes growth of tumor cells. Indeed, CAFs and TAMs
actively participate in altering the growth activity and drug
resistance of tumors in vivo [95, 96]. Guo et al. [97]
recently constructed a gastric cancer mouse model (Gan
mice) by simultaneous activation of prostaglandin E2 and
Wnt signaling in the gastric mucosa. MVD increased
significantly, and the expression of VEGF-A was predom-
inantly induced in the stromal cells of gastric tumors in the
Gan mice. Moreover, they showed by bone marrow
transplantation experiments that a subset of gastric myofi-
broblasts is derived from bone marrow. We examined the
role of MSCs in the tumor microenvironment using
orthotopic nude mice models of gastric and colon cancers.
Systemically administered MSCs possessed the ability to
migrate to the orthotopic tumor site, where they differen-
tiate into CAFs. Tumor cells mixed with MSCs and
implanted orthotopically resulted in a greater tumor volume
and lower survival rate than did implantation of tumor cells
alone (Shinagawa et al., unpublished data).
Epithelial-to-Mesenchymal Transition (EMT)
as a Source of CAFs
EMT is conversion of epithelial cells to migratory fibro-
blastoid cells [98]. Cancer cells undergoing EMT lose
epithelial polarity, acquire a spindle-shaped morphology,
and develop invasive and migratory ability. In various
cancers, EMT is associated with poor histologic differenti-
ation and tumor progression [99, 100]. Several authors have
described the expression patterns of EMT-related genes
such as E-cadherin, β-catenin, S100A4, Snail, Slug, Twist,
and SIP1 in gastric cancer [101–103]. Down-regulation of
E-cadherin expression and high-level of S1004A expression
are associated with peritoneal dissemination, serosal inva-
sion, an infiltrating growth pattern, and a poor prognosis
[103]. Up-regulation of Slug, SIP1, and Snail is associated
with E-cadherin down-regulation in gastric cancer [101,
102]. Using a tissue array method, Kim et al. [104] examined
expression of EMT-related protein in the gastric cancer tissues
of 598 patients and found that loss of epithelial proteins and
acquisition of mesenchymal proteins are associated with
poorly differentiated histology and a poor outcome.
Recent studies revealed that there are genetic alterations
that occur at similar frequencies in both cancer cells and
surrounding stromal cells [105, 106]. In addition, a non-
random X-chromosome-inactivation pattern was found in
both stromal fibroblasts and cancer cells in a breast cancer
model [107]. Thus, cancer cells and a subset of CAFs might
be of the same origin. EMT of cancer cells may also
account for CAFs that are present in tumors.
Future Perspectives
It has been believed that endothelial cells in tumor vessels
are genetically stable and that these cells will not become
drug resistant in response to antivascular therapy. However,
recent studies showed that endothelial cells in certain tumor
vessels are aneuploid and express neoplastic markers [108].
Similarly, it has become clear that CAFs in certain tumors
have somatic gene alterations. We should elucidate whether
genetic and/or epigenetic alterations exist in CAFs and
endothelial cells in tumor vessels.
Gastric cancer-stromal cell interaction 113The different cell types populating the tumor stroma, i.e.,
CAFs, CAMs, endothelial cells, and pericytes, can help to
create an environment permissive of tumor growth, angio-
genesis, and invasion. The evidences presented in this
Review indicate that stromal cells might serve as novel
therapeutic targets in cancer. Targeted therapy that prevents
the stromal support of tumor progression might provide a
complementary approach to conventional treatments that
target the cancer cells themselves. Because most solid
tumors have reactive stroma, targeting of stromal cells may
have broad clinical implications as a therapeutic strategy.
Further understanding the cellular and molecular mecha-
nisms that regulate cancer-stromal cell interaction and
inhibition of stromal cell activation may facilitate develop-
ment of an effective anti-tumor therapy.
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